Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Mouse, Human|
|Host / Isotype||Mouse / IgG|
|Immunogen||Synthetic peptide corresponding to amino acids 154-167 (CSRPSTSSRRRAISE) of human MDM2.|
|Storage buffer||PBS, pH 7.4|
|Contains||0.09% sodium azide|
|Storage Conditions||4°C or -20°C if preferred|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin, Frozen) (IHC (P, F))||1:200-1:500|
|Immunoprecipitation (IP)||Assay dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA1-23318 detects MDM2 in Human samples.
MA1-23318 has been successfully used in Immunohistochemistry (Frozen, Paraffin) and Immunoprecipitation procedures.
MA1-23318 immunogen corresponds to Synthetic peptide corresponding to amino acids 154-167 (CSRPSTSSRRRAISE) of human MDM2.
Clone SMP14 recognizes the 90kDa MDM2 protein. MDM2 forms a complex with p53 which leads to inhibition of p53 function. MDM2 has also been shown to stimulate cellular proliferation via induction of transcriptional regulators including E2F1 and DP1. MDM2 is over expressed in a wide range of human malignancies including soft tissue carcinomas and breast cancer.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo.
MA1-23318 was used in immunohistochemistry to study apoptosis induced by p53 in response to DNA damage and the essential role of c-Myc
|Phesse TJ,Myant KB,Cole AM,Ridgway RA,Pearson H,Muncan V,van den Brink GR,Vousden KH,Sears R,Vassilev LT,Clarke AR,Sansom OJ||Cell death and differentiation (21:956)||2014|
Salivary adenoid cystic carcinoma with an early phase of high-grade transformation: case report with an immunohistochemical analysis.
MA1-23318 was used in immunohistochemistry to report on a case of salivary adenoid cystic carcinoma with high-grade transformation
|Kusafuka K,Miki T,Nakajima T||Diagnostic pathology (8:null)||2013|
Epithelial expression of p53, mdm-2 and p21 in normal lip and actinic cheilitis.
MA1-23318 was used in immunohistochemistry to study changes in the expression of p53 pathway proteins during early lip carcinogenesis
|Martínez A,Brethauer U,Borlando J,Spencer ML,Rojas IG||Oral oncology (44:878)||2008|
Low-grade abdominopelvic sarcoma with myofibroblastic features (low-grade myofibroblastic sarcoma): clinicopathological, immunohistochemical, molecular genetic and ultrastructural study of two cases with literature review.
MA1-23318 was used in immunohistochemistry to examine two cases of low-grade myofibroblastic sarcoma
|Agaimy A,Wünsch PH,Schroeder J,Gaumann A,Dietmaier W,Hartmann A,Hofstaedter F,Mentzel T||Journal of clinical pathology (61:301)||2008|
Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival.
MA1-23318 was used in immunohistochemistry to study the potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia
|Tzouvala M,Lazaris AC,Papatheodoridis GV,Kouvidou C,Papathomas TG,Kavantzas N,Elemenoglou I,Karamanolis DG,Agapitos E||Digestive diseases and sciences (53:451)||2008|
Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
MA1-23318 was used in immunohistochemistry to study the diagnostic and prognostic value of cell cycle regulators in differentiated thyroid cancer
|Melck A,Masoudi H,Griffith OL,Rajput A,Wilkins G,Bugis S,Jones SJ,Wiseman SM||Annals of surgical oncology (14:3403)||2007|
p53 and mdm2 expression in colorectal carcinoma: a correlative analysis with clinical staging and histological parameters.
MA1-23318 was used in immunohistochemistry to investigate the expression and prognostic value of p53 and mdm2 in colorectal carcinoma
|Das P,Vaiphei K,Jain D,Wig JD||International journal of surgical pathology (15:335)||2007|
MDM2 protein expression is a negative prognostic marker in breast carcinoma.
MA1-23318 was used in immunohistochemistry to study the prognostic value of MDM2 protein expression in breast carcinoma
|Turbin DA,Cheang MC,Bajdik CD,Gelmon KA,Yorida E,De Luca A,Nielsen TO,Huntsman DG,Gilks CB||Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc (19:69)||2006|
High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.
MA1-23318 was used in immunohistochemistry to study the role of high thymidylate synthase expression in colorectal cancer with microsatellite instability
|Ricciardiello L,Ceccarelli C,Angiolini G,Pariali M,Chieco P,Paterini P,Biasco G,Martinelli GN,Roda E,Bazzoli F||Clinical cancer research : an official journal of the American Association for Cancer Research (11:4234)||2005|
Coupled induction of iNOS and p53 upregulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgA nephropathy.
MA1-23318 was used in immunohistochemistry to study the involvement of nitric oxide synthase and p53 in the pathogenesis of progressive IgA nephropathy
|Qiu LQ,Sinniah R,Hsu SI||Journal of the American Society of Nephrology : JASN (15:2066)||2004|
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
MA1-23318 was used in immunohistochemistry to study the relationship between mdm2 and p53 expression and response to 5-fluorouracil treatment in advanced colorectal cancer
|Paradiso A,Ranieri G,Simone G,Silvestris N,Costa A,De Lena M,Leone A,Vallejo C,Lacava J||Oncology (62:278)||2002|
Role of P53 and MDM2 in treatment response of human germ cell tumors.
MA1-23318 was used in immunohistochemistry to study the role of p53 and MDM2 in the high sensitivity to chemotherapy of human germ cell tumors
|Kersemaekers AM,Mayer F,Molier M,van Weeren PC,Oosterhuis JW,Bokemeyer C,Looijenga LH||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (20:1551)||2002|
A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene.
MA1-23318 was used in immunohistochemistry to investigate p53 immunoreactivity in ulcerative colitis
|Noffsinger AE,Belli JM,Miller MA,Fenoglio-Preiser CM||Histopathology (39:482)||2001|
Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.
MA1-23318 was used in immunohistochemistry to study the molecular biology of the G1-S cell cycle checkpoint in myxoid and round cell liposarcoma
|Dei Tos AP,Piccinin S,Doglioni C,Vukosavljevic T,Mentzel T,Boiocchi M,Fletcher CD||The American journal of pathology (151:1531)||1997|
Translocation of p53 to mitochondria is regulated by its lipid binding property to anionic phospholipids and it participates in cell death control.
MA1-23318 was used in western blot to study the role of p53 in apoptosis
|Li CH,Cheng YW,Liao PL,Kang JJ||Neoplasia (New York, N.Y.) (12:150)||2010|
NOLC1, an enhancer of nasopharyngeal carcinoma progression, is essential for TP53 to regulate MDM2 expression.
MA1-23318 was used in western blot to investigate the influence of NOLC1 on the regulation of MDM2 expression by TP53
|Hwang YC,Lu TY,Huang DY,Kuo YS,Kao CF,Yeh NH,Wu HC,Lin CT||The American journal of pathology (175:342)||2009|
hTERT antagonizes p53-induced apoptosis independently of telomerase activity.
MA1-23318 was used in western blot to study the role of hTERT in p53-mediated apoptosis
|Rahman R,Latonen L,Wiman KG||Oncogene (24:1320)||2005|
Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway.
MA1-23318 was used in western blot to study the role of Ribosomal protein L11 and oncoprotein MDM2 in a p53-dependent ribosomal-stress checkpoint pathway
|Zhang Y,Wolf GW,Bhat K,Jin A,Allio T,Burkhart WA,Xiong Y||Molecular and cellular biology (23:8902)||2003|
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.
MA1-23318 was used in western blot to study the role of p53 mutants in restoring the replication of an E1B 55-kilodalton protein-deficient adenovirus
|Hann B,Balmain A||Journal of virology (77:11588)||2003|
Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
MA1-23318 was used in immunocytochemistry to study the effect of cancer promoting missense mutations in the MSM2 zinc finger domain on its interaction with L5 and L11 and its ability to induce p53 degradation
|Lindström MS,Jin A,Deisenroth C,White Wolf G,Zhang Y||Molecular and cellular biology (27:1056)||2007|
A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
MA1-23318 was used in immunocytochemistry to investigate the effect of melanoma-predisposing germline CDKN2A mutation on p16 and p14ARF activation
|Hashemi J,Lindström MS,Asker C,Platz A,Hansson J,Wiman KG||Cancer letters (180:211)||2002|
Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53.
MA1-23318 was used in immunocytochemistry to study the effect of mutations in exon 2 of human ARF on its nucleolar localization and ability to regulate nuclear export of MDM2 and p53
|Zhang Y,Xiong Y||Molecular cell (3:579)||1999|
double minute 2, human homolog of; p53-binding protein; hdm2; HDMX; MDM2 oncogene, E3 ubiquitin protein ligase; MDM2 proto-oncogene, E3 ubiquitin protein ligase; Mdm2, p53 E3 ubiquitin protein ligase homolog; Mdm2, transformed 3T3 cell double minute 2, p53 binding protein; MGC5370; MGC71221; oncoprotein Mdm2
ACTFS; hdm2; HDMX; MDM2